News

Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome

February 20, 2018

Minutes Confirm Alignment on Soleno’s Planned Phase III Clinical Trial Soleno In Process of ...

Read More

Soleno Therapeutics Announces $15 Million Private Placement

December 12, 2017

Financing to Support Planned Phase III Clinical Program for DCCR in Prader-Willi Syndrome REDWOOD CITY, ...

Read More

Soleno Therapeutics Announces Joint Venture Agreement for Development and Commercialization of CoSense Monitoring Technology

December 08, 2017

REDWOOD CITY, Calif. , Dec. 08, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical ...

Read More
Soleno – Home